Bandhan Healthcare Fund
Direct · GrowthAI Summary
Bandhan Healthcare Fund has outperformed the NIFTY 50 across all measured periods, with a 1Y Fund CAGR of 14.19% versus the benchmark's -7.05%, generating an alpha of 15.15%. However, lump-sum returns over longer horizons are modest, with the 10Y CAGR at just 1.34%. SIP XIRR data is not available for this fund, so a like-for-like comparison with the category averages (16.71% at 10Y) cannot be made.
The fund exhibits a low beta of 0.55 against the NIFTY 50, with downside capture of just 39.3% versus upside capture of 67.87%, indicating strong cushioning during market declines. Reported drawdown metrics show a maximum drawdown of only -0.087% with zero drawdown events exceeding 10%, though these unusually low figures may reflect a limited measurement window. The positive alpha at 1Y and 3Y suggests recent risk-adjusted outperformance, though alpha turns negative beyond 7Y.
Detailed holdings and sector allocation data are not available for this fund. As a healthcare sectoral fund, it invests in pharmaceutical, hospital, and diagnostics companies, which inherently concentrates exposure in a single sector rather than diversifying across the broader market. Investors should review the latest factsheet for current top holdings and concentration levels.
Direct comparison with the category is limited because the fund's SIP XIRR is unavailable, while the category averages range from 14.1% (1Y) to 16.95% (5Y). The fund's positive alpha over 1Y and 3Y periods indicates competitive recent performance versus its benchmark. Long-term lump-sum CAGRs below 2% suggest the fund has struggled to compound meaningfully over extended periods, a common challenge for sectoral strategies.
This fund is suitable only as a satellite allocation for investors with high risk tolerance and conviction in the healthcare sector, not as a core portfolio holding. Sectoral funds like this one are best held with a long time horizon of 5-7 years or more, given the cyclicality of healthcare themes. Investors should be comfortable with periods of significant underperformance relative to diversified equity funds.
- Strong downside protection with a beta of 0.55 and downside capture of only 39.3% versus the NIFTY 50
- Impressive 1Y alpha of 15.15%, with the fund returning 14.19% CAGR while the benchmark declined 7.05%
- Low expense ratio of 0.87% for a sectoral fund in the direct plan
- Very low long-term lump-sum returns, with CAGRs of just 1.34% over 10Y and 0.89% over 15Y, and negative alpha beyond 7Y
- Single-sector concentration in healthcare exposes investors to theme-specific regulatory and pricing risks
- SIP XIRR and rolling return data are unavailable, limiting the ability to assess performance against category peers
Generated on 05-09-2026, 3:02 AM. Verify before investing.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
Not enough data to compute SIP returns.
Not enough data to compute rolling returns.
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +15.15 | 0.55 | 67.9% | 39.3% | 14.2% | -7.0% |
| 3 Years | +2.92 | 0.55 | 67.9% | 39.3% | 4.5% | -2.4% |
| 5 Years | +0.56 | 0.55 | 67.9% | 39.3% | 2.7% | -1.4% |
| 7 Years | -0.44 | 0.55 | 67.9% | 39.3% | 1.9% | -1.0% |
| 10 Years | -1.18 | 0.55 | 67.9% | 39.3% | 1.3% | -0.7% |
| 12 Years | -1.48 | 0.55 | 67.9% | 39.3% | 1.1% | -0.6% |
| 15 Years | -1.76 | 0.55 | 67.9% | 39.3% | 0.9% | -0.5% |